Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management

American Journal of Kidney Diseases

Volumn 35, Issue 6, 2000, Pages 1226-1237

  Block, Geoffrey A ^a,b   Port, Friedrich K ^a  

^a Denver Nephrologists   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Coronary artery disease; Dialysis; Mortality; Phosphate binders; Secondary hyperparathyroidism (SHPT); Vascular calcification; Vitamin D

Indexed keywords

CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; R 568; UNCLASSIFIED DRUG; VITAMIN D;

CALCIFICATION; CHRONIC KIDNEY FAILURE; HEART DEATH; HEMODIALYSIS PATIENT; HYPERPHOSPHATEMIA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; RENAL OSTEODYSTROPHY; REVIEW; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; UREMIA; VASCULAR DISEASE;

EID: 0034084251     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(00)70064-3     Document Type: Article

References (87)

1. E Slatopolsky S Caglar JP Pennell On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog J Clin Invest 50 1971 492 499
2. WE Bloembergen Cardiac disease in chronic uremia: Epidemiology Adv Ren Replace Ther 4 1997 185 193
3. US Renal Data System USRDS 1999 Annual Data Report 1999 The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD and
4. RN Foley PS Parfrey MJ Sarnak Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 suppl 3 1998 S112 S119
5. US Renal Data System USRDS 1999 Annual Data Report Am J Kidney Dis (suppl 1) 32 1998 The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD S1 S162 also in 1998
6. EG Lowrie NL Lew Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 15 1990 458 482
7. GA Block TE Hulbert-Shearon NW Levin FK Port Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: A national study Am J Kidney Dis 31 1998 607 617
8. M Boaz S Smetana Regression equation predicts dietary phosphorus intake from estimate of dietary protein intake J Am Diet Assoc 96 1996 1268 1270
9. M Rufino E deBonis M Martin S Rebollo B Martin R Miquel M Cobo D Hernandez A Torres V Lorenzo Is it possible to control hyperphosphatemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 13 1998 65 67
10. CH Hsu Are we mismanaging calcium and phosphate metabolism in renal failure Am J Kidney Dis 29 1997 641 649
11. F Llach B Nikakhtar Methods of controlling hyperphosphatemia in patients with chronic renal failure Curr Opin Nephrol Hypertens 2 1993 365 371
12. JA Delmez E Slatopolsky Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease Am J Kidney Dis 19 1992 303 317
13. MV Rocco L Easter R Makoff Management of hyperphosphatemia with calcium based binders Semin Dial 12 1999 195 201
14. JF Winchester C Rotellar M Goggins D Robino TA Rakowski WP Argy Calcium and phosphate balance in dialysis patients Kidney Int 43 1993 S174 S178
15. CA DeSoi JG Umans Phosphate kinetics during high flux hemodialysis J Am Soc Nephrol 4 1993 1214 1218
16. SH Hou J Zhao CF Ellman Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate Am J Kidney Dis 18 1991 217 224
17. VSS Lim MJ Flanigan J Fangman Effect of hematocrit on solute removal during high efficiency hemodialysis Kidney Int 37 1990 1557 1562
18. M Emmett MD Sirmon WG Kirkpatrick CR Nolan GW Schmitt MB Cleveland Calcium acetate control of serum phosphorus in hemodialysis patients Am J Kidney Dis 17 1991 544 550
19. MJ Janssen A van der Kuy PM ter Wee WP van Boven Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients Clin Nephrol 45 1996 111 119
20. F Meric P Yap MJ Bia Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy Am J Kidney Dis 16 1990 459 464
21. AJ Bleyer SK Burke M Dillon B Garrett KS Kant D Lynch SN Rahman P Schoenfeld I Teitelbaum S Zeig E Slatopolsky A comparison of the calcium free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients Am J Kidney Dis 33 1999 694 701
22. E Slatopolsky S Caglar L Gradowska On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intake Kidney Int 2 1972 147 151
23. S Lopez-Hilker A Dusso N Rapp Phosphorus restriction reverses secondary hyperparathyroidism in chronic renal failure independent of changes in calcium and 1,25 dihydroxycholecalciferol Am J Physiol 259 1990 F432 F437
24. E Slatopolsky A Dusso AJ Brown The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure Am J Med Sci 317 1999 370 376
25. DM Kates DJ Sherrard DL Andress Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure Am J Kidney Dis 30 1997 809 813
26. E Slatopolsky J Finch M Denda Phosphate restriction prevents parathyroid cell growth in uremic rats: High phosphate directly stimulates PTH secretion in vitro J Clin Invest 96 1995 2534 2540
27. T Navey-Many R Rahamimov N Livini J Silver Parathyroid cell proliferation in normal and chronic renal failure rats: The effects of calcium, phosphate, and vitamin D J Clin Invest 96 1995 1786 1793
28. E Moallem R Kilav J Silver RNA protein binding and post transcriptional regulation of parathyroid gene expression by calcium and phosphorus J Biol Chem 9 1998 5253 5259
29. M Denda J Finch E Slatopolsky Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure Am J Kidney Dis 38 1996 596 602
30. F Takahashi J Finch AJ Brown E Slatopolsky The effects of a low phosphorus diet on the secretion of PTH in establishing diffuse parathyroid hyperplasia J Am Soc Nephrol 8 1997 580A (abstr)
31. HC Anderson Calcific diseases Arch Pathol Lab Med 107 1983 341 348
32. T Drueke A clinical approach to the uraemic patient with extraskeletal calcifications Nephrol Dial Transplant 11 1996 37 42
33. L Wexler B Brundage J Crouse R Detrand V Fuster J Maddahi J Rumberger W Stanford R White K Tauberg Coronary artery calcification: Pathophysiology, epidemiology, imaging methods and clinical implications: A statement for health professionals from the American Heart Association Circulation 94 1996 1175 1192
34. S Bro K Olgaard Effects of excess PTH on nonclassical target organs Am J Kidney Dis 30 1997 606 620
35. SG Rostand TB Drueke Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure Kidney Int 56 1999 383 392
36. S Bro K Olgaard PTH: One can teach an old hormone new tricks Nephrol Dial Transplant 12 1997 2222 2223
37. R Baczynski SG Massry R Kohan M Magott Y Saglikes N Brautbar Effect of parathyroid hormone on myocardial energy metabolism in the rat Kidney Int 27 1985 718 725
38. E Bogin J Levi I Harary SG Massry Effects of parathyroid hormone on oxidative phosphorylation of heart mitochondria Miner Electrolyte Metab 7 1982 151 156
39. SG Rostand C Sanders KA Kirk EA Rutsky RG Fraser Myocardial calcification and cardiac dysfunction in chronic renal failure Am J Med 85 1988 651 657
40. AR Thompsono J Fallon S Nussbaum Evaluation of metastatic cardiac calcification in a model of chronic primary hyperparathyroidism Surgery 108 1990 1047 1051
41. Amman J Tornig C Flechtenmacher Blood pressure independent all intramyocardial arterioles in experimental uremia-evidence for a permissive action of PTH Nephrol Dial Transplant 10 1995 2043 2048
42. K Amman M-L Gross GM London E Ritz Hyperphosphatemia: A silent killer of patients with renal failure? Nephrol Dial Transplant 14 1999 2085 2087
43. S Wessels K Amman J Tornig E Ritz Cardiovascular structural changes in uremia: Implications for cardiovascular function Semin Dial 12 1999 288 292
44. Y Nishizawa T Shoji T Kawagishi H Morii Atherosclerosis in uremia: Possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation Kidney Int 52 suppl 62 1997 S90 S92
45. U Querfeld MM Hoffmann G Klaus F Eifinger M Ackerrschott D Michalk PA Kern Antagonistic effects of vitamin D and parathyroid hormone on lipoprotein lipase in cultured adipocytes J Am Soc Nephrol 10 1999 2158 2164
46. J Bommer E Strohbeck J Georich M Bahner I Zuna Arteriosclerosis in dialysis patients Int J Artif Organs 19 1996 638 644
47. JA Rumberger BH Brundage DJ Rader G Kondos Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons Mayo Clin Proc 74 1999 243 252
48. R Narang D Ridout C Nonis JS Kooner Serum calcium, phosphorus, and albumin levels in relation to angiographic severity of coronary artery disease Int J Cardiol 60 1997 73 79
49. J Braun M Oldendorf W Moshage R Heidler E Zeitler FC Left Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients Am J Kidney Dis 27 1996 394 401
50. M Utsunomiya Angiographic study of stenosis and calcification of coronary vessels in long term dialysis patients: Examination of risk factors for coronary calcification Nippon Jinzo Gakkai Shi 38 1996 155 163
51. NW Levin TE Hulberg-Shearon RL Strawderman FK Port Which causes of death are related to hyperphosphatemia in hemodialysis patients J Am Soc Nephrol 9 1998 217A (abstr)
52. F Llach Cardiac calcification: Dealing with another risk factor in patients with kidney failure Semin Dial 12 1999 293 295
53. RN Foley PS Parfrey JD Harnett GM Kent CJ Martin DC Murray PE Barre Clinical and echocardiographic disease in patients starting end stage renal disease therapy Kidney Int 47 1995 186 192
54. DC Kuzela WE Huffer JD Conger SD Winter WS Hammond Soft tissue calcification in chronic dialysis patients Am J Pathol 86 1977 402 424
55. J Huting Mitral valve calcification as an index of left ventricular dysfunction in patients with end stage renal disease on peritoneal dialysis Chest 105 1994 383 388
56. J Huting Predictive value of mitral and aortic valve sclerosis for survival in end stage renal disease on continuous ambulatory peritoneal dialysis Nephron 64 1993 63 68
57. S Ribeiro A Ramos A Brandao Rebelo Jr A Guerra C Resina A Vila-Lobos F Carvacho F Remedio F Rireird Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism Nephrol Dial Transplant 13 1998 2037 2040
58. S Mazzaferro G Coen S Bandini PP Borgatti M Ciaccheri D Diacinti E Ferranti T Lusenti G Mancini I Monducci M Pasquali F Pellegrini I Perrucca F Taggi GA Cinotti Role of aging, chronic renal failure and dialysis in the calcification of mitral annulus Nephrol Dial Transplant 8 1993 335 340
59. AJ Bleyer M Choi B Igwemezie E de ka Torre WL White A cast control study of proximal calciphylaxis Am J Kidney Dis 32 1998 376 383
60. R Perez-Mijares JL Guzman-Zamudio J Payan-Lopez A Rodriguez-Fernandez P Gomez-Fernandez M Almarez-Jimenez Calciphylaxis in a haemodialysis patient: Functional protein S deficiency? Nephrol Dial Transplant 11 1996 1856 1859
61. F Llach Calcific uremic arteriolopathy (calciphylaxis): An evolving entity? Am J Kidney Dis 32 1998 514 518
62. DJA Goldsmith A Covic PA Sambrook P Ackrill Vascular calcification in long-term hemodialysis patients in a single unit: A retrospective analysis Nephron 77 1997 37 43
63. T Kawagishi Y Nishizawa T Konishi K Kawasaki T Shoji T Tabata T Inoue H Morii High resolution B mode ultrasonography in evaluation of atherosclerosis in uremia Kidney Int 48 1995 820 826
64. T Savage AL Clarke M Giles CRV Tomson AEG Raine Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease Nephrol Dial Transplant 13 1998 2004 2012
65. M Akmal RR Barndt AN Ansari JG Mohler SG Massry Excess PTH in CRFF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy Kidney Int 47 1995 158 163
66. AJ Hutchison Calcitriol lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy Perit Dial Int 9 suppl 2 1999 S408 S412
67. JA Delmez J Kelber KY Norword KS Giles E Slatopolsky Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study Kidney Int 49 1996 163 167
68. CM Weaver DG Schulze LW Peck HM Magnusen BR Martin SE Gruenhagen Phosphate binding capacity of ferrihydrite versus calcium acetate in rats Am J Kidney Dis 34 1999 324 327
69. N Kuboyama Y Watanabe M Yamaguchi K Sato T Suzuki T Akiba Effects of neritrol on faecal and urinary phosphate excretion in normal rats Nephrol Dial Transplant 14 1999 610 614
70. R Birck E Zimmerman S Wassmer R Nowack FJ Van Der Woude Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphatemia in patients on maintenance hemodialysis: A crossover study Nephrol Dial Transplant 14 1999 1475 1479
71. S Kuroda M Komori K Nagamatsu R Ninomiya K Maejima K Hasegawa M Samejima M Kuroda H Fusimori M Kasai T Saruta Effect of iron as a new type of phosphate binder in hemodialysis patients Jpn J Nephrol 37 1995 468 473
72. O Hergesell E Ritz Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients Nephrol Dial Transplant 14 1999 863 867
73. CH Hsu SR Patel EW Young New phosphate binding agents: Ferric compounds J Am Soc Nephrol 10 1999 1274 1280
74. EA Slatopolsky SK Burke MA Dillon RenaGel, a nonabsorbed calcium and aluminum free phosphate binder, lowers serum phosphorus and parathyroid hormone Kidney Int 55 1999 299 307
75. GM Chertow SK Burke MA Dillon E Slatopolsky Long-term effects of sevelamer hydrochloride on the calcium x phosphorus product and the lipid profile of hemodialysis patients Nephrol Dial Transplant 14 1999 2907 2914
76. AJ Brown Vitamin D analogues Am J Kidney Dis 32 suppl 2 1998 S25 S39
77. 2 (Paticalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis J Am Soc Nephrol 9 1998 1427 1432
78. F Llach G Keshav MV Goldblat JS Lindberg R Sadler J Delmez J Arruda A Lau E Slatopolsky Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2 Am J Kidney Dis 32 suppl 2 1998 S48 S54
79. AU Tan BS Levine RB Mazess DM Kyllo CW Bishop JC Knutson KS Kleinman JW Coburn Effective suppression of parathyroid hormone by 1-alpha-hydroxyvitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism Kidney Int 51 1997 317 323
80. JM Frazao RW Chesney JW Coburn Intermittent oral 1-alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients Nephrol Dial Transplant 13 1998 68 72
81. JE Antonsen DJ Sherrard DL Andress A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Kidney Int 53 1998 223 227
82. EF Nemeth ME Steffey LG Hammerland Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc Natl Acad Sci U S A 95 1998 4040 4045
83. DJ Sherrard Calcimimetics in action Kidney Int 53 1997 510
84. C Velentzas H Meindok DG Oreopoulos HE Meema S Rabinovich M Jones D Sutton A Rapoport GA deVeber Visceral calcification and the CaXP product Adv Exp Med Biol 103 1978 195 201
85. DL Andress New therapies raise new issues for lowering parathyroid hormone levels in uremic patients Semin Dial 12 1999 282 284
86. I Mucsi G Hercz R Uldall M Ouwendyk R Francoeur A Pierratos Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis Kidney Int 53 1998 1399 1401
87. A Pierratos Daily hemodialysis: Why the renewed interest? Am J Kidney Dis 32 suppl 4 1998 S76 S82